← Markets

Zenas BioPharma, Inc.

ZBIO · NASDAQ

Market closed$29.53$1.29 (+4.57%)After hours $29.74 · +0.71%

Key statistics

Previous close$28.24
Open$27.90
Day high$30.26
Day low$27.71
52-week high$44.60
52-week low$13.50
Market cap1.32B
Volume718.80K
Average volume743.13K
P/E ratio-5.87
Forward P/E—
EPS-5.03
Dividend yield0.00%

Market context

Why it moved

ZBIO shares surged following the announcement of inducement equity grants — including stock options and RSUs for newly hired employees — which signaled strong talent acquisition momentum and growing institutional confidence in the company's late-stage autoimmune disease pipeline, with obexelimab and orelabrutinib as key candidates.

MarketbeatMarketbeatInstagramMarketbeatQuiverquant

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Zenas BioPharma surged after Wedbush reiterated its Outperform rating with a $45 price target, arguing the bear case overlooks obexelimab's commercial potential — estimating the addressable market could be ~75% larger than previously thought. Wedbush highlighted obexelimab's favorable safety profile, lower steroid use, and reduced treatment costs versus Amgen's Uplizna, and flagged several upcoming catalysts including INDIGO vaccine sub-study data, Phase 2 SunStone trial results in lupus, and healthy volunteer data for oral IL-17 inhibitor ZB021. The company also announced inducement equity grants to new hires, signaling active talent expansion as it advances its autoimmune pipeline.

4.568

July 15, 2026Zenas BioPharma gained over 3% as a Seeking Alpha analysis highlighted obexelimab's potential to anchor a broad autoimmune franchise beyond rare disease, reinforcing investor optimism around the company's B-cell inhibition platform across multiple indications. The move came despite a mixed healthcare backdrop—XLV closed under pressure amid sector earnings headwinds and geopolitical-driven macro volatility—suggesting ZBIO's outperformance was driven by company-specific pipeline conviction. In after-hours trading, shares held nearly flat near the session close.

3.2281

July 14, 2026Zenas BioPharma declined amid a broadly risk-off session, as renewed U.S.-Iran military tensions sent oil prices surging and weighed on equities. The pullback comes despite a strong fundamental backdrop for ZBIO: a recent Phase 3 INDIGO trial success for obexelimab in IgG4-Related Disease—meeting all primary and secondary endpoints with a 56% flare risk reduction—and a Biologics License Application already submitted to the FDA. Goldman Sachs and Jim Cramer have both highlighted biotech as a sector poised for continued M&A and innovation-driven gains, underscoring longer-term tailwinds for the company.

-2.9923

July 11, 2026Zenas BioPharma fell amid a mixed session for biotech, as broader sector enthusiasm—highlighted by Jim Cramer calling biotech 'the hottest group in the market'—failed to lift the clinical-stage immunology company. Shares declined against a backdrop of recent positive momentum catalysts: a June Phase 3 trial success, a court dismissal of an IPO-era securities lawsuit, and newly added Russell Growth Index membership following a 58% one-month surge. Valuation concerns (price-to-book of 5.2x flagged as elevated) and macro headwinds including Medicaid spending cuts under the One Big Beautiful Bill—expected to cloud biotech revenue projections—may be tempering enthusiasm.

-2.3445

July 9, 2026Zenas BioPharma closed up over 2%, buoyed by a dismissed securities lawsuit over IPO disclosures and a sweeping reclassification into Russell growth indexes. A federal judge in Massachusetts threw out the IPO-related securities class action, removing a key legal overhang for the clinical-stage immunology company. Meanwhile, its recent addition to the Russell 2000 Growth and Russell 3000 Growth indexes is drawing index-fund flows, though analysts caution the stock appears overvalued at a 5.2x price-to-book ratio versus a peer average of 3.4x. Broader biotech sentiment remains constructive, with Jim Cramer calling the sector 'the hottest group in the market' and M&A activity accelerating under a more favorable FDA backdrop. Near-term catalysts for Zenas still hinge on regulatory decisions around its obexelimab BLA filing in IgG4-RD and ongoing trial readouts.

2.2941

July 9, 2026Zenas BioPharma gained nearly 4% in regular trading, lifted by a confluence of favorable developments including the dismissal of a federal securities lawsuit over IPO disclosures and its reclassification into Russell Growth indexes — a shift that can redirect institutional index-tracking flows toward the stock. The moves come amid a broader rotation into biotech, with Jim Cramer calling it "the hottest group in the market" and M&A activity accelerating under a more permissive FDA. However, shares are giving back some gains in after-hours, slipping roughly 2.6%, as escalating U.S.-Iran tensions and surging oil prices sparked a broader risk-off session; analysts also flag ZBIO's 5.2x price-to-book as expensive relative to biotech peers.

3.9198

July 8, 2026Zenas BioPharma gained nearly 5%, with the stock continuing to rise in after-hours trading, buoyed by a powerful confluence of tailwinds: its recent reclassification from Russell value to Russell growth indices (including Russell 2000 Growth and Russell 3000 Growth), a surging healthcare sector that has led the S&P 500 for two consecutive weeks, and growing biotech M&A optimism after Jim Cramer called biotech "the hottest group in the market" amid a more favorable FDA regulatory environment. Above-average volume suggests institutional interest may be tied to index-tracking flows from its growth index inclusion, even as investors weigh the company's ongoing losses, going-concern language, and reliance on external funding.

4.6503

July 3, 2026Zenas BioPharma declined amid a mixed session on Wall Street, where semiconductor weakness dragged on the Nasdaq while healthcare emerged as the strongest S&P sector on the day. The pullback follows a notable run-up tied to the company's recent addition to multiple Russell growth indices on June 29, including the Russell Microcap Growth and Russell 2500 Growth benchmarks, and a prior June 3 Phase 3 clinical win where its obexelimab candidate met primary and secondary endpoints in the Indigo trial for IgG4-Related Disease. With 8 analysts maintaining Buy ratings and an average price target of $42.12—implying roughly 55% upside from current levels—investor attention remains focused on ZBIO's pipeline progress even as the stock retraces from recent gains on roughly double its average trading volume.

-2.75

Finimize · July 17, 2026Wedbush Thinks Zenas BioPharma Is Still MispricedMoomoo · July 17, 2026Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush SaysSeeking Alpha · July 14, 2026Zenas BioPharma: Obexelimab Could Build An Autoimmune Franchise (NASDAQ:ZBIO)Pluang · July 14, 2026Zenas BioPharma shows promising Phase 3 results for autoimmune drug obexelimab, boosting growth outlook.Bloomberg Law News · June 30, 2026Zenas BioPharma Shakes IPO Investor’s Cash Burn Rate LawsuitThe Clinical Trial Vanguard · June 18, 2026Zenas BioPharma Files FDA Application for Obexelimab in IgG4-RDMoomoo · June 3, 2026H.C. Wainwright Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $44Investing.com · June 3, 2026H.C. Wainwright reiterates Zenas Biopharma stock rating at buy
Mt Newswire · July 17, 2026Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says
Mt Newswire · June 3, 2026Zenas BioPharma's Potential Autoimmune Disease Treatment Meets Primary, Secondary Endpoints in Phase 3 Study
Mt Newswire · May 28, 2026Zenas BioPharma Submits Obexelimab Application in Immunoglobulin G4-Related Disease
Benzinga · May 28, 2026Zenas BioPharma Submits An FDA Biologics License Application For Obexelimab In Immunoglobulin G4-Related Disease
Benzinga · May 19, 2026Zenas BioPharma Announces That Safety And Efficacy Outcomes From The Phase 3 INDIGO Trial Will Be Presented At The European Alliance Of Associations For Rheumatology Congress, June 3-6
Mt Newswire · May 19, 2026Zenas BioPharma Insider Bought Shares Worth $1,012,800, According to a Recent SEC Filing
Benzinga · May 14, 2026Morgan Stanley Maintains Equal-Weight on Zenas BioPharma, Raises Price Target to $22
Mt Newswire · May 13, 2026Zenas BioPharma Doses First Patient in Phase 1 Trial of Autoimmune Conditions

Peers

S&P 500SPX · $7,457.69-1.01%Ligand Pharmaceuticals IncorporatedLGND · $303.39+2.34%Celldex Therapeutics, Inc.CLDX · $35.35-0.14%BioCryst Pharmaceuticals, Inc.BCRX · $9.29+2.03%argenx SEARGX · $860.55+0.30%TG Therapeutics, Inc.TGTX · $54.87-0.11%Vir Biotechnology, Inc.VIR · $9.43+0.32%Inhibrx Biosciences Inc.INBX · $87.39-1.89%BridgeBio Pharma, Inc.BBIO · $81.38+1.34%Ionis Pharmaceuticals, Inc.IONS · $54.39-0.48%Roivant Sciences Ltd.ROIV · $34.51+1.71%Immatics N.V.IMTX · $9.59+2.02%